Astrazeneca Invests $3.5B In R&D And Manufacturing In The United States

AstraZeneca today announces $3.5B of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 B of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy.

AstraZeneca’s expanding footprint in the US includes, among others:

• A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts
• A next generation manufacturing facility for biologics in Maryland
• Cell therapy manufacturing capacity on the West and East Coasts
• Specialty manufacturing in Texas

Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”

Delivering growth: Ambition 2030
These US investments are the first of a series of important steps to help deliver AstraZeneca’s ambition to achieve $80B in Total Revenue by 2030 as set out in May this year. A key element of our strategy is accelerating the Company’s development in the United States. The US is AstraZeneca’s largest market, generating 44% of its Total Revenue.¹

About AstraZeneca in the US
AstraZeneca has approximately 17,800 employees working across 17 R&D, manufacturing and commercial sites spanning 12 states.

^1. As at Q3 2024 noted in AstraZeneca Q3 Financial Results. Available at: https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html. Accessed November 2024.